Kimer Med

Kimer Med is a New Zealand biotech company, developing a pipeline of novel, broad-spectrum antiviral drug candidates. With success against 21 different viruses so far, we’re taking on the global health challenge of viral disease and future pandemic threats. Our vision is to end the immense suffering caused by viral disease. There are currently around 270 viruses that cause disease in humans, and only 13 of them have an approved antiviral treatment available. In other words, 95% of viral diseases lack any approved treatment, resulting in enormous unmet medical needs worldwide. We have built and optimised a proprietary platform for the rapid development of broad-spectrum antiviral drug candidates to address these massive medical needs. Our goal is to bring to market a family of broad-spectrum antivirals to treat multiple diseases, and provide pandemic protection. To date we have achieved efficacy against 21 different viruses spanning 9 virus families, and proved the broad-spectrum capabilities of our platform. We are currently in the lead-optimisation phase and nearing phase 1 clinical trials. In 2024, Kimer Med was recognised as one of Fierce Biotech's 'Fierce 15 of 2024' - the best and brightest of biotech. We are also the recipient of a Merck Emerging Biotech Grant, and multiple grants from Callaghan Innovation.